Amphastar Pharma (AMPH) Tops Q2 EPS by 11c

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.85, $0.11 better than the analyst estimate of $0.74. Revenue for the quarter came in at $174.4 million versus the consensus estimate of $173.95 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Thunder Mountain Gold plans $6.4M private placement for South Mountain
• Zhipu AI prices HK offering at HK$1,588/share - Reuters